These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26427518)

  • 21. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
    Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA
    J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MAOIs and transdermal delivery.
    Vandenberg CM
    J Clin Psychiatry; 2012 Sep; 73(9):e28. PubMed ID: 23059160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal selegiline for the treatment of major depressive disorder.
    Lee KC; Chen JJ
    Neuropsychiatr Dis Treat; 2007; 3(5):527-37. PubMed ID: 19300583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
    Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
    J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commentary on the treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
    Carlat DJ
    Psychopharmacol Bull; 2007; 40(3):29-31. PubMed ID: 18007566
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials.
    Pae CU; Patkar AA; Jang S; Portland KB; Jung S; Nelson JC
    CNS Spectr; 2014 Aug; 19(4):324-9. PubMed ID: 24168807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Goldberg JF; Portland KB
    J Affect Disord; 2013 Nov; 151(2):409-417. PubMed ID: 23890583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
    Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD
    J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
    Mawhinney M; Cole D; Azzaro AJ
    J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral versus transdermal selegiline: antidepressant-like activity in rats.
    Gordon MN; Muller CD; Sherman KA; Morgan DG; Azzaro AJ; Wecker L
    Pharmacol Biochem Behav; 1999 Jul; 63(3):501-6. PubMed ID: 10418793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 32. A case report of high-dose transdermal selegiline in the treatment of major depressive disorder.
    Ashton AK
    Ann Clin Psychiatry; 2009; 21(1):51-2. PubMed ID: 19239833
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.
    Blob LF; Sharoky M; Campbell BJ; Kemper EM; Gilmor MG; VanDenberg CM; Azzaro AJ
    CNS Spectr; 2007 Jan; 12(1):25-34. PubMed ID: 17192761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Feb; 47(2):146-58. PubMed ID: 17244765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selegiline transdermal system in major depressive disorder: profile report.
    Frampton JE; Plosker GL
    CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230
    [No Abstract]   [Full Text] [Related]  

  • 36. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
    Elkashef A; Fudala PJ; Gorgon L; Li SH; Kahn R; Chiang N; Vocci F; Collins J; Jones K; Boardman K; Sather M
    Drug Alcohol Depend; 2006 Dec; 85(3):191-7. PubMed ID: 16730924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
    J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transdermal selegiline in patients receiving electroconvulsive therapy.
    Horn PJ; Reti I; Jayaram G
    Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seligiline transdermal system in depression.
    Goodnick PJ
    Expert Opin Pharmacother; 2007 Jan; 8(1):59-64. PubMed ID: 17163807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translating the evidence on atypical depression into clinical practice.
    Hyman Rapaport M
    J Clin Psychiatry; 2007; 68 Suppl 3():31-6. PubMed ID: 17348765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.